Skip to content

Braveheart Bio

US · BRVE #2845 by market cap Listed 2026
20.39 +1.12 +5.81%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

About Braveheart Bio

Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.

Founded
2024
CEO
Dr. Travis Murdoch, M.D.
Employees
30
Headquarters
San Francisco, California, United States of America
Fiscal year end
12-31
Website
braveheart.bio

Company profile

Exchange
US
Symbol
BRVE
Market-cap rank
#2845
Listing date
2026-08-06
Market cap
1.83B
Float cap
382.31M
Shares out
89.87M
Float shares
18.75M

Sectors & themes

Browse all sectors & themes

Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.

Braveheart Bio discussion 0 comments

Add a comment